Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. Pamela J. McShane, MD, explores the clinical ...

DPP1 inhibitor Brinsupri (brensocatib), given as a once-daily oral tablet, became the first therapy approved by the FDA for ...

The list of new medicines recommended for approval at the October meeting of the EMA's human medicines committee includes Brinsupri, the first treatment for serious chronic lung disease non-cystic ...

For Barb, who has been living with bronchiectasis for nearly 20 years, shortness of breath and an uncontrollable cough were a ...

Bronchiectasis is characterised by irreversible dilatation of the bronchi, chronic sputum production and recurrent exacerbations that drive progressive lung damage. Management aims to break the cycle ...

Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas ...

Infex Therapeutics is pushing ahead with the development of a non-cystic fibrosis bronchiectasis (NCFB) drug candidate after ...

Bronchiectasis is a progressive inflammatory lung condition. Symptoms resemble those of more common respiratory conditions.

The American Thoracic Society (ATS) today announced a major quality improvement initiative aimed at tackling the persistent and widespread underdiagnosis of bronchiectasis in the United States. As the ...

Phase 3b ENCORE data assess inhaled amikacin in MAC lung disease. Read more on efficacy, safety, and patient-reported ...

Infex Therapeutics announces positive phase IIa study results for RESP-X in NCFB patients colonised with Pseudomonas aeruginosa: Cheshire, UK Saturday, May 23, 2026, 18:00 Hrs [IS ...

What are the most attractive biotech stocks right now for investors? Seeking Alpha analysts offer their picks. Read more here.